Besponsa

Chemical Nameinotuzumab ozogamicin
Dosage FormInjectable (intravenous; 0.9 mg/vial)
Drug ClassMonoclonal antibodies
SystemBlood
CompanyWyeth Pharmaceuticals
Approval Year2017

Indication

  • Besponsa is indicated for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia.
Last updated on 10/22/2020

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
NCCN guidelines version 1.2020. Acute lymphoblastic leukemia.2020NCCN evidence blocks